Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Nucleic Acids and Circulating Rare Cells: Liquid Biopsy for Early Cancer Detection

Steve Soper's Biography



Steve Soper, Foundation Distinguished Professor, Director, Center of BioModular Multi-scale System for Precision Medicine, The University of Kansas

Prof. Steven A. Soper received his Ph.D. from the University of Kansas in 1989 followed by a Postdoctoral Fellowship at Los Alamos National Laboratory, where he worked on single-molecule detection for high speed sequencing of the human genome. In 1991, he joined the faculty at Louisiana State University (LSU) within the Department of Chemistry, where he filled the William H. Pryor Distinguished Chair of Chemistry. Prof. Soper also had a joint appointment in the Mechanical Engineering Department and Department of Biological Sciences. While at LSU, he founded the Center for BioModular Multi-Scale Systems, which has as its primary charge to develop enabling and transformative tools for making environmental and health-related measurements at unprecedented speeds with full process automation directly in the field. Some of these tools include monitoring air and food/water supplies for biopathogens, determining bacterial/viral infections of unknown strains in patients, evaluating brain damage/injury, sampling blood for rare cells, such as tumor cells, and their molecular analysis and sequencing genomes in near real time. These tools consist of microfluidic and nanofluidic devices make in polymers via micro- or nanoreplication.

Prof. Soper is currently Foundation Distinguished Professor, Director, Center of BioModular Multi-scale System for Precision Medicine at the University of Kansas. Prof. Soper also holds a joint appointment at Ulsan National Institute of Science and Technology in Ulsan, South Korea, where he is a World Class University Professor. Prof. Soper is currently the Editor of the Americas for the Analyst and on the Editorial Board for Journal of Fluorescence and Journal of Micro- and Nanosystems. Prof. Soper is currently serving as a permanent Member of the Nano study panel with the National Institutes of Health. As a result of his efforts, Prof. Soper has secured extramural funding totaling $45M and has published over 295 manuscripts (h index = 44) and is the author of ten patents. He is also the founder of a startup company, BioFluidica, which is marketing devices for the isolation and enumeration of rare cells. His list of awards includes Chemical Instrumentation by the American Chemical Society, the Benedetti-Pichler Award, Fellow of the AAAS, Fellow of Applied Spectroscopy, Fellow of the Royal Society of Chemistry, R&D 100 Award, Distinguished Masters Award at LSU and Outstanding Scientist/Engineer of Louisiana in 2001. Finally, Prof. Soper has granted 40 PhDs and 5 MS students under his direction.

Steve Soper Image

Extracellular Vesicles (EVs) and Cell Free DNA (cfDNA) as Blood-based Biomarkers: Plastic-based Microfluidics for their Enrichment and Analysis

Wednesday, 28 March 2018 at 12:30

Add to Calendar ▼2018-03-28 12:30:002018-03-28 13:30:00Europe/LondonExtracellular Vesicles (EVs) and Cell Free DNA (cfDNA) as Blood-based Biomarkers: Plastic-based Microfluidics for their Enrichment and AnalysisSELECTBIOenquiries@selectbiosciences.com

While there are a plethora of different blood-based markers, EVs are generating significant interests due to their relatively high abundance (~1013 particles per mL of blood) and the information they carry. EVs contain a diverse array of nucleic acids, such as mRNA, lncRNA, and miRNA that can be used for disease management. In addition to EVs, cfDNA also are biomarkers that can be used to help manage different disease states using the mutations they possess that can have high diagnostic value. In spite of the relatively high abundance of cfDNA in diseased patients (~160 ng/mL), the extraction and enrichment of cfDNA has been inefficient, even by commercial kits, due to the low abundance of the tumor bearing DNA fragments (<0.01%) and the short nature of these fragments, especially cancer-related cfDNA (as small as 50 bp). In this presentation, we will discuss the design, fabrication and analytical figures-of-merit of a microfluidic device that can serve the dual purpose for the affinity-based selection of EVs and the solid phase extraction of cfDNA directly from plasma using the same device. The microfluidic is made from a plastic that can be injection molded to produce high quality devices at low cost. For EVs, the device is made cyclic olefin copolymer (COC) is UV/O3 activated to allow for the efficient immobilization of affinity agents to the surface of the device. In the case of cfDNA, the device is made from COC as well, but is only UV/O3 activated (i.e., no affinity agents used). Information will be provided as to the ability to molecularly profile the cargo contained within the affinity-selected EVs, in particular mRNA expression profiling. We will also discuss the use of this microfluidic to isolate with high recovery cfDNA from plasma samples with size selection capabilities. The isolated cfDNA could be queried for mutations using an allele-specific ligation detection reaction at a mutant to wild-type ratio <0.1%.


Add to Calendar ▼2018-03-28 00:00:002018-03-29 00:00:00Europe/LondonCirculating Nucleic Acids and Circulating Rare Cells: Liquid Biopsy for Early Cancer Detection SELECTBIOenquiries@selectbiosciences.com